PCE

PCP-class dissociatives are documented to cause dose-dependent hypertension and tachycardia. PCE's additional dopamine and noradrenaline reuptake inhibition may compound cardiovascular stress. Individuals with pre-existing cardiovascular disease, including hypertension, coronary artery disease, or heart failure, face elevated risk of acute cardiovascular events.

NMDA receptor antagonism can lower seizure threshold, particularly at high doses. PCP-class compounds are documented to cause seizures in overdose settings. Individuals with epilepsy or other seizure disorders face increased risk of breakthrough seizures.

PCE's NMDA receptor blockade and dopamine reuptake inhibition both independently contribute to psychotogenesis. Community reports consistently warn of a significantly elevated rate of psychosis and mania compared to other dissociatives. Individuals with a history of psychotic disorders (schizophrenia, schizoaffective disorder, brief psychotic disorder) are at extreme risk of symptom exacerbation or relapse.

PCE undergoes extensive hepatic metabolism via hydroxylation and glucuronide conjugation, with CYP2B6 as the likely primary enzyme. Hepatic impairment would reduce clearance, prolong duration of effects, and increase the risk of toxic accumulation. PCP-class chronic use is also associated with liver abnormalities.

Renal excretion of PCP-class compounds is pH-dependent, with urinary acidification increasing clearance. Impaired renal function would reduce elimination rate and prolong exposure, potentially increasing toxicity risk.

PCP is teratogenic in animal models. NMDA receptors play critical roles in neurodevelopment, and blockade during gestation may impair fetal brain development. No human teratogenicity data exist for PCE specifically.

PCE acts as a serotonin reuptake inhibitor at the arylcyclohexylamine class level. Co-administration with monoamine oxidase inhibitors could produce dangerous serotonin accumulation. No case reports exist, but the theoretical mechanism warrants absolute contraindication classification.

Rhabdomyolysis is a documented complication of PCP intoxication, particularly in cases involving agitation, physical exertion, or high doses. Individuals with a prior history of rhabdomyolysis may be at elevated risk of recurrence. PCE's high potency and prolonged duration increase the window of vulnerability.